Chenguang Biotech Group Co.Ltd(300138) : independent opinions of independent directors on the company's use of some idle raised funds to temporarily supplement working capital

Chenguang Biotech Group Co.Ltd(300138)

Independent directors' opinions on using some idle raised funds to temporarily supplement working capital

Independent opinion of

As an independent director of Chenguang Biotech Group Co.Ltd(300138) (hereinafter referred to as "the company"), based on the principle of prudence and independent judgment, in accordance with the rules for independent directors of listed companies, the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 - standardized operation of GEM listed companies, the articles of association and other relevant provisions, We hereby express the following independent opinions on the company's use of some idle raised funds to temporarily supplement working capital:

1、 Independent opinions on using some idle raised funds to temporarily supplement working capital

The company uses the temporarily idle raised funds of no more than 325 million yuan of "natural plant comprehensive extraction integration project (phase I)" to temporarily supplement the working capital for a period of no more than 12 months, which is in line with the Listing Rules of GEM stocks of Shenzhen Stock Exchange Relevant requirements such as self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 - standardized operation of companies listed on GEM; It will not affect the normal progress of the investment projects with raised funds, and there is no situation that changing the investment direction of raised funds in a disguised form will damage the rights and interests of the company and all shareholders (especially minority shareholders); It is conducive to improving the use efficiency of the raised funds and reducing the financial expenses of the company. It is agreed that the company will use the temporarily idle raised funds of no more than 325 million yuan to temporarily supplement the working capital for a period of no more than 12 months.

Independent directors: Liu Zhanglin, Zhou Fangsheng, Wang Shuhong February 19, 2022

- Advertisment -